Inhaled drug that dissolves airway mucus plugs
Raised to date
$5M
of $5M offered across 1 Form D filing
Aer Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of innovative therapies targeting mucus-related issues in lung diseases. The company's primary focus is on creating inhalable treatments to address airway mucus plugs, which are common in conditions like COPD and asthma.
The company stands out due to its use of advanced lung imaging and analysis techniques to identify patients with airway mucus plugs, offering a specialized and targeted approach to lung health.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Feb 7, 2025 | Equity | $5M/ $5M | Form D |
Inhaled Mucolytic Therapy
AER-01 is a lead therapeutic candidate designed to dissolve mucus plugs in the airways of patients with severe respiratory diseases. Developed through extensive academic collaborations, it is an inhaled thiol-saccharide mucolytic agent intended to improve lung function and ease breathing difficulties.
Built for
Patients with chronic respiratory diseases
